You prepare IND/CTA applications by assembling nonclinical data, CMC documentation, clinical protocols, and investigator credentials, then formatting and submitting them to regulators for approval.
This article provides you with a clear, executive-level process to structure IND and CTA submissions. You’ll learn the essential requirements, timelines, and best practices that minimize regulatory delays and increase your chance of approval.
What is the difference between an IND and a CTA?
An IND (Investigational New Drug application) is the regulatory pathway in the United States, required before testing an investigational drug in humans. It is filed with the FDA and typically supports multiple clinical protocols under one umbrella application.
A CTA (Clinical Trial Application) is the equivalent outside the U.S., including Europe, Canada, and other global regions. Unlike an IND, a CTA is protocol-specific—meaning you must submit a new CTA for each trial.
The structural difference is critical: INDs follow a modular dossier system in eCTD format, while CTAs require a protocol, the Investigator’s Brochure (IB), and an Investigational Medicinal Product Dossier (IMPD). Recognizing this distinction early helps you avoid duplicative work across regions.
Gather Preclinical Data
Your submission begins with solid nonclinical data. Regulators want proof that the investigational drug is safe enough for human trials.
This data comes from GLP-compliant pharmacology and toxicology studies, covering safety pharmacology, single-dose and repeat-dose toxicology, genotoxicity, and reproductive studies when appropriate. You also need ADME studies (absorption, distribution, metabolism, excretion) to define exposure and clearance.
Without these studies, regulators will not allow you to proceed. A well-organized toxicology summary, aligned with ICH M3 guidance, ensures clarity for reviewers.
Assemble CMC Documentation
The Chemistry, Manufacturing, and Controls (CMC) section is often the most scrutinized. Regulators expect a clear description of your drug’s composition, manufacturing process, and quality controls.
Your CMC package should include:
- A description of the drug substance and drug product.
- Validation of analytical methods.
- Stability studies with real-time and accelerated data.
- Specifications for impurities and process controls.
CMC preparation is where many applications face delays. Start early and plan for scalability—regulators want assurance that your process is not only safe but also reproducible.
Develop the Clinical Protocol
The clinical protocol is the roadmap for your trial. It must justify your study design, dosing regimen, safety monitoring, and statistical approach.
For an IND, you may submit several protocols under one application. For CTAs, each protocol requires its own filing. Include the following essentials:
- Trial objectives and endpoints.
- Inclusion and exclusion criteria.
- Dose justification based on animal-to-human extrapolation.
- Safety reporting mechanisms.
Regulators evaluate whether your trial protects participants and generates meaningful data. Weak or vague protocols are a common reason for clinical holds.
Prepare the Investigator’s Brochure and Supporting Documents
Your Investigator’s Brochure (IB) summarizes the clinical and nonclinical data available to date. It guides investigators in trial conduct and patient safety.
Beyond the IB, your dossier should also contain:
- Investigator qualifications and CVs.
- IRB or ethics committee approvals.
- Informed Consent Forms (ICFs).
- Compliance forms ensuring adherence to Good Clinical Practice (GCP).
This documentation demonstrates operational readiness and ethical oversight, which regulators weigh heavily.
Engage Regulators Before Submission
One of the most effective ways to avoid rejection is to meet with regulators early. A Pre-IND meeting with the FDA or a scientific advice meeting with EMA or national authorities allows you to align on expectations.
These interactions clarify whether your toxicology package is sufficient, whether your CMC plan meets quality standards, and whether your trial design raises concerns.
Skipping this step often leads to unnecessary delays. When you engage early, you gain insight into regulatory thinking and can adjust your submission before formal review.
Submit in the Correct Format
An IND must be submitted in electronic Common Technical Document (eCTD) format. The FDA enforces strict rules on sequence numbers, metadata, and module placement.
A CTA is typically submitted through the Clinical Trial Information System (CTIS) in Europe or national portals elsewhere. The CTA dossier includes the protocol, IB, IMPD, and informed consent materials.
Formatting errors can lead to technical rejections, wasting months. Invest in electronic publishing expertise to ensure compliance with FDA and EMA standards.
Anticipate Review Timelines and Regulatory Feedback
Once filed, the FDA has 30 days to review an IND. During this period, the agency may issue a clinical hold if deficiencies are found. The hold remains until you address the concerns.
For CTAs in Europe, timelines vary by country but typically fall between 15 and 30 days. Some countries also allow tacit approval if no objections are raised within the set period.
Timely responses to queries and proactive communication with authorities determine whether your program proceeds on schedule or faces costly delays.
Maintain and Update Your IND/CTA
Submission is only the beginning. Regulators expect amendments and safety updates throughout the clinical program.
For INDs, you must submit annual reports, safety updates, and protocol amendments. For CTAs, you submit substantial modifications whenever you adjust protocols, doses, or manufacturing.
Maintaining your file with accuracy and timeliness demonstrates regulatory discipline and builds trust with authorities.
Key Steps for IND/CTA Preparation
- Gather preclinical safety and efficacy data
- Compile CMC quality documentation
- Draft clinical trial protocols
- Ensure regulatory compliance formatting
- Submit electronically via appropriate authority portals
In Conclusion
When you prepare an IND or CTA, treat it as more than a filing—it is the foundation of your clinical development program. By aligning preclinical data, CMC documentation, and trial protocols into a clear, regulator-ready submission, you minimize risk, accelerate approval, and secure a strong start for your clinical trials.
For more updates on regulatory strategy, clinical trial best practices, and biotech leadership, follow me on Facebook, where I share insights and resources to support life sciences innovation.
Nirdosh Jagota is the Consultant & Managing Partner, GRQ Biotech Advisors. Nirdosh Jagota has over 30 years of experience in biotech and pharmaceutical industries, leading innovation in regulatory affairs and quality management.
Dr. Nirdosh Jagota has led global teams across US, Europe, Asia Pacific, Latin America, China, India, and Japan. His expertise has been instrumental in the successful submission, approval, and lifecycle management of biologics, small molecules, and vaccines.